 | • レポートコード：MRC2305A098 • 出版社/出版日：Transparency Market Research / 2023年3月13日 • レポート形態：英文、PDF、207ページ • 納品方法：Eメール（納期：要問合せ） • 産業分類：製薬 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本市場調査資料によると、世界の高脂血症治療薬市場規模が、2023年の120億ドルから2031年には201億ドルまで年平均6.1%成長すると見込まれています。本資料は高脂血症治療薬の世界市場について広く調査し、序論、仮定、調査方法、エグゼクティブサマリー、市場概要、新型コロナウイルス感染症分析、治療薬種類別（スタチン、胆汁酸捕捉剤、コレステロール吸収阻害剤、フィブリン酸誘導体、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況、主要ポイントなどをまとめています。また、本資料には、AbbVie, Inc.、Amgen, Inc.、AstraZeneca plc、Bristol-Myers Squibb Company、Daiichi Sankyo Company, Limited、Dr. Reddy’s Laboratories Ltd.、Merck & Co., Inc.、Mylan N.V、Pfizer, Inc.、Sanofi S.A.、Esperion Therapeutics、CJ Healthcare、Novartisなどの企業情報が含まれています。 ・序論 ・仮定 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・新型コロナウイルス感染症分析 ・世界の高脂血症治療薬市場規模：治療薬種類別 - スタチンの市場規模 - 胆汁酸捕捉剤の市場規模 - コレステロール吸収阻害剤の市場規模 - フィブリン酸誘導体の市場規模 - その他治療薬種類の市場規模 ・世界の高脂血症治療薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界の高脂血症治療薬市場規模：地域別 - 北米の高脂血症治療薬市場規模 - ヨーロッパの高脂血症治療薬市場規模 - アジア太平洋の高脂血症治療薬市場規模 - 中東・アフリカの高脂血症治療薬市場規模 - 中南米の高脂血症治療薬市場規模 ・競争状況 ・企業情報 ・主要ポイント |
Antihyperlipidemic Drugs Market – Scope of Report
TMR’s report on the global antihyperlipidemic drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global antihyperlipidemic drugs market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global antihyperlipidemic drugs market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the antihyperlipidemic drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global antihyperlipidemic drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global antihyperlipidemic drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global antihyperlipidemic drugs market.
The report delves into the competitive landscape of the global antihyperlipidemic drugs market. Key players operating in the global antihyperlipidemic drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global antihyperlipidemic drugs market profiled in this report.
Key Questions Answered in Global Antihyperlipidemic Drugs Market Report
• What is the sales/revenue generated by antihyperlipidemic drugs across all regions during the forecast period?
• What are the opportunities in the global antihyperlipidemic drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Antihyperlipidemic Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global antihyperlipidemic drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global antihyperlipidemic drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global antihyperlipidemic drugs market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Antihyperlipidemic Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Antihyperlipidemic Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Industry Events
5.3. Regulatory Scenario by Region/Globally
5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Antihyperlipidemic Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Statins
6.3.2. Bile Acid Sequestrants
6.3.3. Cholesterol Absorption Inhibitors
6.3.4. Fibric Acid Derivatives
6.3.5. PCSK9 Inhibitors
6.3.6. Miscellaneous Antihyperlipidemic Agents
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Antihyperlipidemic Drugs Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Antihyperlipidemic Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Antihyperlipidemic Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2017–2031
9.2.1. Statins
9.2.2. Bile Acid Sequestrants
9.2.3. Cholesterol Absorption Inhibitors
9.2.4. Fibric Acid Derivatives
9.2.5. PCSK9 Inhibitors
9.2.6. Miscellaneous Antihyperlipidemic Agents
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Antihyperlipidemic Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2031
10.2.1. Statins
10.2.2. Bile Acid Sequestrants
10.2.3. Cholesterol Absorption Inhibitors
10.2.4. Fibric Acid Derivatives
10.2.5. PCSK9 Inhibitors
10.2.6. Miscellaneous Antihyperlipidemic Agents
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Antihyperlipidemic Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2031
11.2.1. Statins
11.2.2. Bile Acid Sequestrants
11.2.3. Cholesterol Absorption Inhibitors
11.2.4. Fibric Acid Derivatives
11.2.5. PCSK9 Inhibitors
11.2.6. Miscellaneous Antihyperlipidemic Agents
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Antihyperlipidemic Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Statins
12.2.2. Bile Acid Sequestrants
12.2.3. Cholesterol Absorption Inhibitors
12.2.4. Fibric Acid Derivatives
12.2.5. PCSK9 Inhibitors
12.2.6. Miscellaneous Antihyperlipidemic Agents
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Antihyperlipidemic Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Statins
13.2.2. Bile Acid Sequestrants
13.2.3. Cholesterol Absorption Inhibitors
13.2.4. Fibric Acid Derivatives
13.2.5. PCSK9 Inhibitors
13.2.6. Miscellaneous Antihyperlipidemic Agents
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. AbbVie, Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Amgen, Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. AstraZeneca plc
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Bristol-Myers Squibb Company
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Daiichi Sankyo Company Limited
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Dr. Reddy’s Laboratories Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Merck & Co., Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Mylan N.V
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Pfizer, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Sanofi S.A.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. Financial Overview
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Esperion Therapeutics
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Product Portfolio
14.3.11.3. Financial Overview
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. CJ Healthcare
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Product Portfolio
14.3.12.3. Financial Overview
14.3.12.4. SWOT Analysis
14.3.12.5. Strategic Overview
14.3.13. Novartis
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Product Portfolio
14.3.13.3. Financial Overview
14.3.13.4. SWOT Analysis
14.3.13.5. Strategic Overview